Poor animal study design and reporting raise concerns about whether current processes are the best way to conduct effective and efficient drug development.
Charles River Laboratories and PathoQuest have expanded their strategic partnership to help move vaccine, biologic, and gene-therapy candidates through the drug discovery and development pipeline.
ImmunoPrecise Antibodies has acquired ModiQuest Research BV to create a “single source provider of services across the full antibody discovery value chain,” says CRO.
The synthetic DNA provider Twist Bioscience Corporation has completed a private placement of $50m to advance its proprietary, silicon-based DNA Synthesis Platform.
PPD has expanded its Middleton, WI-based GMP analytical laboratory, increasing its large molecule development capacity with space for more than 100 new employees.
Syngene International has signed a multiyear agreement with GSK through which the companies will focus on accelerating the discovery of new drug candidates using the CRO’s discovery services platforms.
Envigo is increasing its surgical footprint ten-fold to create a West Coast Center of Excellence for surgery and supply myocardial infarction research models regionally.
Covance has formed a global immunology and immunotoxicology (I&I) unit, which will be dedicated to the “innovative and complex” approaches required by biologics, says CRO.
The non-clinical contract research organization (CRO) Citoxlab Group has acquired Solvo Biotechnology, a CRO specializing in drug transporters studies and the assessment of drug-drug interactions (DDI).
Trans-Hit Bio and Q&T Research have entered into an exclusive strategic partnership, which will provide biopharma customers with access to human biospecimens, for which there is “a great demand,” says exec.
